ClinicalTrials.gg
Not yet recruitingNCT07730346Updated Jul 28, 2026

Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.

A Phase 3 interventional study of Sebaloxavir marboxil and Placebo in Influenza Prevention, sponsored by Nanjing Zenshine Pharmaceuticals. Not yet recruiting at 1 site in China. Open to participants aged 2 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-28.

Sponsored by Nanjing Zenshine Pharmaceuticals · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
858
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Planned enrollment
49th of 157
858 · median 360
Started
2026
with 14 others
Phase 3
46 of 173
9 open now
Primary completion
2027-12
later than 33 of 36 live
Registered
163rd of 173
by date
Lead sponsor
6 of 173
Nanjing Zenshine Pharmaceuticals

Among the 173 studies in Influenza, Human with a site in China, this one is the 49th largest by planned enrollment of the 157 interventional ones that give a count, is one of 15 that started in 2026, is one of 46 in phase 3, reaches primary completion later than 33 of the 36 other live ones, and was the 163rd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 2 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC). A total of 536 index participants (the first person in the household diagnosed with influenza) and 858 household contacts (family members living with the index participant) are planned to be enrolled. After the index participants and their household contacts have signed informed consent form and passed screening eligibility, randomization will be performed at the household level in a 1:1 ratio, stratifying by the time from onset of the index participant's initial influenza symptoms to signing of informed consent form (\<24 hours, ≥24 hours), index participant's viral subtype (influenza A, influenza B), and household contact's age (\<12 years, ≥12 years). Household contacts will be assigned to either the Sebaloxavir marboxil group or the placebo group. The study objective is to compare the prophylactic efficacy and safety of Sebaloxavir marboxil tablets/oral suspension versus placebo in household contacts (HHCs).

03

Conditions studied

  • Influenza Prevention

Browse trials for

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Index Participants:

Inclusion Criteria:

  • 1. The index participant (aged ≥18 years), or the index participant (aged \<18 years) together with their legal guardian, understands and voluntarily provides written form (ICF). The index participant must be ≥1 year of age at the time of ICF signing, with no gender restriction.
  • 2. The index participant must be the first case of influenza virus infection in the household during the current influenza season.
  • 3. The index participant must have a positive result from a rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR) assay.
  • 4. At the time of HHC randomization, the interval from the onset of the index participant's initial influenza symptoms to informed consent must be ≤48 hours. Symptom onset is defined as: first axillary temperature ≥37.5°C, or the presence of at least one other influenza symptom.
  • 5. The index participant must not have used any anti-influenza antiviral medications (including traditional Chinese medicines or Western medicines) since symptom onset, and must be willing to receive oseltamivir phosphate treatment after signing informed consent form.

Exclusion Criteria:

  • 1. Participants who are diagnosed with bacterial or other non-influenza virus infections at screening requiring systemic antibacterial or antiviral treatment;
  • 2. Participants with suspected to the active ingredients or of oseltamivir phosphate oral suspension/capsules.

Household contact:

Inclusion Criteria:

  • 1. Aged ≥2 years at the time of randomization, with no gender restriction;
  • 2. Has been living in the same household with the index participant for at least 48 hours at the time of randomization;
  • 3. Is able to reside with the index participant from screening/randomization through Day 10 (must live in the same household with the index participant for at least 7 days);
  • 4. Tests negative by rapid influenza diagnostic test (RIDT) or polymerase chain reaction (PCR);
  • 5. Meets all of the following criteria and is judged by the investigator to have no influenza virus infection:

    1. Axillary temperature \<37°C at screening;
    2. No influenza-related symptoms at screening (such as nasal congestion, sore throat, cough, myalgia or arthralgia, fatigue, headache, chills/sweating, or other influenza symptoms assessed by the investigator);
  • 6. The HHC is ≥18 years of age, or the HHC is \<18 years of age and together with their parent(s)/legal guardian(s) understands and voluntarily signs the informed consent form (ICF), and agrees to comply with all study procedures, including completion of diary cards (the guardian may assist in assessment/completion).
  • 7. The HHC must sign the informed consent form (ICF) within 24 hours after the index participant signs the ICF;
  • 8. The HHC and their partner must agree to practice complete abstinence or use effective measures from screening through 3 months after the end of study drug administration.

Exclusion Criteria:

  • 1. Participants with suspected hypersensitivity to the active pharmaceutical ingredients or excipients of the product;
  • 2. Participants whose household contacts or other family members (excluding the index participant) have been diagnosed with influenza within 3 months before randomization;
  • 3. Participants who have been cohabiting with other family members exhibiting influenza-like symptoms (axillary temperature ≥37.5°C, nasal congestion, sore throat, cough, myalgia/arthralgia, fatigue, headache, chills/sweating, or other influenza symptoms as assessed by the investigator) other than on the screening day;
  • 4. Participants requiring systemic (oral or injectable) or intranasal antipyretic/analgesic agents, , or (those using topical preparations are allowed);
  • 5. Participants who have received an influenza vaccine within 6 months prior to screening;
  • 6. Participants who have taken anti-influenza Chinese or Western medications within 30 days prior to screening, including but not limited to neuraminidase inhibitors, hemagglutinin inhibitors, M2 ion channel blockers, cap-dependent endonuclease (CEN) inhibitors, and heat-clearing/detoxifying Chinese herbal medicines, such as oseltamivir, zanamivir, peramivir, laninamivir, umifenovir, favipiravir, rimantadine, amantadine, arbidol, nitazoxanide, baloxavir, Lianhua Qingwen capsules/granules, Jinhua Qinggan granules*, etc.
  • 7. Participants with active infection or requiring systemic anti-infective treatment at screening (topical therapy for mild skin infections is allowed).
  • 8. Participants with other respiratory viral infections.
  • 9. Participants with difficulty swallowing study medication or a history of gastrointestinal disorders that may significantly impair drug absorption, including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, or post-gastrectomy.
  • 10. Participants with severe underlying comorbidities, defined as Grade 3 or higher per the (CTCAE) Version 6.0.
  • 11. Immunocompromised participants, including those with , history of organ or bone marrow transplantation, infection, or use of immunosuppressants within the previous 3 months.
  • 12. HHCs requiring long-term use of aspirin- or salicylate-containing products, defined as daily regular use for more than 14 consecutive days.
  • 13. Participants with suspected or confirmed alcohol abuse (defined as weekly consumption of >14 units of alcohol; 1 unit = 360 mL beer, 45 mL of 40% spirits, or 150 mL of 12% wine) or history of drug abuse.
  • 14. Participants who have participated in another interventional clinical trial of a drug or medical device within 30 days before screening.
  • 15. Women who have a positive pregnancy test result or are currently lactating.
  • 16. Participants with any other conditions that, in the judgment of the investigator, would preclude enrollment in the study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
858 participants (estimated)

Study arms

  • Experimental
    Sebaloxavir marboxil group

    Drug: Sebaloxavir marboxil

  • Placebo comparator
    Placebo group

    Drug: Placebo

Interventions

  • Dosing Regimen for Household Contacts: Sebaloxavir marboxil tablets/oral suspension is administered based on age as follows: * 18 years: Single dose, Sebaloxavir marboxil tablets: 2 tablets; * 12 years and \<18 years: Single dose, Sebaloxavir marboxil tablets: 1 tablet; * 2 years and \<12 years: Single dose, Sebaloxavir marboxil oral suspension, administered according to body weight.

  • DrugPlacebo

    Dosing Regimen for Household Contacts: Household contacts will receive the placebo of Sebaloxavir marboxil tablets/oral suspension based on age as follows: * 18 years: Single dose, placebo of Sebaloxavir marboxil tablets: 2 tablets; * 12 years and \<18 years: Single dose, placebo of Sebaloxavir marboxil tablets: 1 tablet; * 2 years and \<12 years: Single dose, placebo of Sebaloxavir marboxil oral suspension, administered according to body weight.

06

What researchers measure

Primary outcomes

  1. The percentage of household contacts (HHCs) with PCR-positive influenza virus infection accompanied by fever (axillary temperature ≥37.5°C) and at least one additional influenza symptom (e.g., nasal congestion, sore throat, cough) after dosing.

    Time frame: From day1 up to day10

Secondary outcomes

  1. Percentage of HHCs with PCR-positive influenza virus infection but no influenza symptoms after dosing.

    Time frame: From day1 up to day10

  2. Percentage of HHCs with PCR-positive influenza virus infection accompanied by fever (axillary temperature ≥37.5°C) or at least one other influenza symptom after dosing.

    Time frame: From day1 up to day10

  3. Time from dosing to PCR-positive influenza virus infection accompanied by fever or at least one other influenza symptom after dosing.

    Time frame: From day1 up to day10

  4. Time from dosing to meeting the primary endpoint criteria (influenza virus infection accompanied by fever [axillary temperature ≥37.5°C] and at least one other influenza symptom).

    Time frame: From day1 up to day10

  5. Percentage of households with at least one HHC achieving the primary endpoint criteria after dosing, relative to all households.

    Time frame: From day1 up to day10

  6. Incidence of all adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Time Frame: From day1 up to day15

Other outcomes

  1. Plasma concentration of ZX-7101

    Time frame: On Day5 and Day 15

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 13 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 28, 2026
StartEst.
Nov 7, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jan 30, 2028
Last update
Jul 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07730346
Lead sponsor
Nanjing Zenshine Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 28, 2026
Start date
Nov 7, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jan 30, 2028 (estimated)
Last update
Jul 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sebaloxavir marboxil

Start the discussion